[Observations on current surgical viewpoints in gynecological and breast oncology].

Radical surgery in gynaecological and mammary cancerology exists one century. Better results as longer survival and disease free intervals are the consequences of the progress of scientific and technical advancement. The five-year survival for the total group (stages I to IV) of malignant tumours in a personal series is 65% and the ten-year survival 53%.

One aspect of surgical quality assurance: complications in gynaecologic and mammary surgery.

This overview of the operative and post-operative complications encountered in a personal series of 10.190 classical surgical procedures out of 43.395 patients gives an idea about the nature and rate of problems in the classical way of surgery.

[Influence of surgical quality in the treatment of cancer of the ovary and fallopian tubes].

229 patients with ovarian cancer (224) or Fallopian tube cancers (5) are discussed. 51.3% of 115 patients of 224 had stages III and IV, 4 patients with stage IIIc had Fallopian tube cancer.

DNA ploidy and the expression of tissue-carcinoembryonic antigen in grade III carcinoma of the breast.

A series of 50 Stage I and II, Grade III ductal carcinomas of the breast was characterized by DNA flow cytometry and further analyzed with a monoclonal antibody for carcinoembryonic antigen (CEA). The antigen was detected with the indirect immunoperoxidase technique on paraffin sections and on cytologic smears of the cell suspensions that were used for flow cytometric DNA analysis. A significant higher incidence of CEA-positivity in cytologic smears and tissue sections was found in DNA-diploid tumors (13/18 and 12/18, respectively) than in DNA-aneuploid tumors (13/22 and 12/32, respectively) (P less than 0.

Prostacyclin/thromboxane ratio in human breast cancer.

In this prospective follow-up study the prognostic value of the tumor prostacyclin/thromboxane ratio in human breast carcinoma was investigated. The stable degradation products of prostacyclin and thromboxane (6-keto-PGF1 alpha and TXB2, respectively), were measured by radio-immunoassay in homogenized primary tumours from 29 patients with primary non-metastatic breast cancer. The median follow-up was 43 months (range 24-58 months).